- In June 2023, Centogene N.V. expanded its collaboration with Agios Pharmaceuticals to develop improved therapies for genetically validated diseases using PYRUKYND (mitapivat). This first-in-class selective small molecule activator of the pyruvate kinase enzyme was approved by the U.S. FDA in February 2021
- In May 2023, Unipath Specialty Laboratory in India launched the HRD Gene Panel utilizing SOPHiA GENETICS technology. This initiative is expected to contribute significantly to advancements in the cancer genomics field
- In April 2023, Agilent Technologies, Inc. introduced an NGS assay designed for somatic variant profiling across various solid tumors, which aims to enhance precision oncology through comprehensive genomic profiling (CGP)
- In May 2022, Illumina Inc. added a companion diagnostic kit to its CE-marked product list. This was Europe’s first-in-class IVD TruSight Oncology (TSO) comprehensive assay to receive the CE mark distinction
- In March 2022, Eurofins Genomics supported ‘Our Future Health’, the UK’s largest health analysis program, to genotype five million people and build an extensive representation of the UK’s population health. This initiative aims to aid in the prevention, diagnosis, and treatment of diseases
